MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Eagle Pharmaceuticals Company Profile (NASDAQ:EGRX)

Consensus Ratings for Eagle Pharmaceuticals (NASDAQ:EGRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $84.80 (133.16% upside)

Analysts' Ratings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016MizuhoDowngradeBuy -> Neutral$66.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016RBC CapitalReiterated RatingBuy$78.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Piper JaffrayReiterated RatingOverweight$98.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/31/2016William BlairReiterated RatingOutperform$109.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015Cantor FitzgeraldReiterated RatingBuy$95.00 -> $92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415$0.30$0.07$20.78 million$18.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.57)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115$1.47$1.31$3.41 million$36.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2015($0.49)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/17/2014Q314($0.49)($0.65)$2.81 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.37)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.02$0.02$0.02
Q2 20161$1.01$1.01$1.01
Q3 20161$1.58$1.58$1.58
Q4 20161$1.99$1.99$1.99
(Data provided by Zacks Investment Research)
Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Eagle Pharmaceuticals (NASDAQ:EGRX)
DateHeadline
06/25/16 03:38 PMHow Analysts Feel About Eagle Pharmaceuticals Inc (NASDAQ:EGRX)? - Press Telegraph
06/25/16 07:38 AMALERT: Rosen Law Firm Reminds Eagle Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - EGRX - Business Wire (press release)
06/24/16 08:15 PMSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Eagle Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – EGRX - [GlobeNewswire] - STEVENSON, Md., June 24, 2016-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court ...
06/24/16 02:55 PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – EGRX - [GlobeNewswire] - NEW YORK, June 24, 2016-- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. and certain of its officers. The class action, filed in United States District ...
06/24/16 11:13 AMINVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Action Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - EGRX - [GlobeNewswire] - NEW YORK, June 24, 2016-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, ...
06/23/16 06:24 PMSHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - [Business Wire] - Goldberg Law PC announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. .
06/23/16 02:32 PMALERT: Rosen Law Firm Reminds Eagle Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - EGRX - [Business Wire] - Rosen Law Firm, a global investor rights law firm, reminds purchasers of Eagle Pharmaceuticals, Inc. securities from February 23, 2016 through March 18, 2016, both dates inclusive of the important August 1, 2016 lead plaintiff deadline in the class action.
06/23/16 06:16 AMEagle Pharmaceuticals (NASDAQ:EGRX) target price reduced to $47 as covered today by Mizuho Securities - Breaking Finance News
06/22/16 04:51 PMIMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - [Business Wire] - Goldberg Law PC announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. .
06/22/16 03:56 PMRecently Issued Stock Ratings For Eagle Pharmaceuticals Inc (EGRX) - Fiscal Standard
06/22/16 01:39 PMINVESTOR ALERT: Investigation of Eagle Pharmaceuticals Inc. Announced by Law Offices of Howard G. Smith - [Business Wire] - Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. concerning the Company and its officers’ possible violations of federal securities laws.
06/22/16 01:39 PMINVESTOR ALERT: Investigation of Eagle Pharmaceuticals Inc. Announced by Law Offices of Howard G. Smith - [Business Wire] - Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. concerning the Company and its officers’ possible violations of federal securities laws.
06/21/16 03:37 PMEagle Pharmaceuticals (NASDAQ:EGRX) target price reduced to $47 as covered today by Mizuho Securities
06/21/16 08:27 AMHere's Why Mizuho Downgraded Eagle Pharmaceuticals Inc (EGRX) - Smarter Analyst
06/21/16 08:27 AMEAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ ... - GlobeNewswire (press release)
06/21/16 07:36 AMEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : June 21, 2016 -
06/21/16 03:00 AMEAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1, 2016 Lead Plaintiff Deadline in Securities Class Action - [GlobeNewswire] - SAN FRANCISCO, June 21, 2016-- The following statement is being issued by Hagens Berman Sobol Shapiro LLP:. To: All persons or entities who purchased or otherwise acquired securities of Eagle Pharmaceuticals ...
06/20/16 03:06 PMEagle Pharma Downgraded On 'Challenging' Hospital Environment -
06/20/16 12:22 PM6 Biggest Mid-Day Losers For Monday -   GlobeImmune Inc (NASDAQ: GBIM) shares tumbled 22.72 percent to $2.55. Vista Gold Corp. (NYSE: VGZ) shares fell 10.34 percent to $1.30. Gold futures declined 0.51 percent to $1,288.30 an ounce. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) ...Full story available on Benzinga.com
06/20/16 10:52 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 – EGRX - [GlobeNewswire] - NEW YORK, June 20, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Eagle Pharmaceuticals, Inc. between ...
06/20/16 04:44 AMEagle Pharma downgraded by Mizuho -
06/19/16 03:33 PMEagle Pharmaceuticals Inc (EGRX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 07:46 AMEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Yearly Sales Projections At $429.085 - Investor Newswire
06/16/16 03:48 PMInvestor News: Lawsuit against Eagle Pharmaceuticals Inc (NASDAQ:EGRX) filed
06/16/16 08:07 AMEagle Pharmaceuticals Inc (EGRX) Current Analyst Ratings - Fiscal Standard
06/15/16 03:50 PMEagle Pharmaceuticals (EGRX) Showing Signs Of Perilous Reversal Today - TheStreet.com
06/15/16 03:50 PMEagle Pharmaceuticals' Overlooked Asset - Seeking Alpha
06/15/16 09:03 AMINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX - [Accesswire] - NEW YORK, NY / ACCESSWIRE / June 15, 2016 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Eagle Pharmaceuticals, ...
06/14/16 03:43 PMLast Traded Price Fluctuations: DexCom, Inc. (NASDAQ:DXCM) , Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Street Updates
06/14/16 03:43 PMEarnings Analysis to see: FirstMerit Corporation (NASDAQ:FMER), Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) - Beacon Chronicle
06/14/16 10:52 AMSHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims Against Eagle Pharmaceuticals Inc. And Advises Investors With Losses To Contact The Firm - [Business Wire] - Goldberg Law PC announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. .
06/14/16 08:39 AMDrug Generic Gainers- Sophiris Bio (NASDAQ:SPHS), Eagle Pharmaceuticals (NASDAQ:EGRX) - Seneca Globe
06/13/16 03:36 PMEarnings Stocks Analysis: Eagle Pharmaceuticals Inc. (NASDAQ:EGRX), Immunomedics Inc. (NASDAQ:IMMU) - Beacon Chronicle
06/13/16 03:36 PMAnalysis under consideration: Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) - News Oracle
06/13/16 01:42 PMEagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : June 13, 2016 -
06/13/16 07:59 AMEagle Pharmaceuticals Inc. (NASDAQ:EGRX) surged 27.80%: Armstrong Flooring, Inc. (NYSE:AFI), The Walt Disney ... - KC Register
06/13/16 07:59 AMNoticeable Analyst's ideas: Boston Scientific Corporation (NYSE:BSX) , Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Street Updates
06/13/16 07:59 AMHC Stocks News: Allergan plc Ordinary Shares (NYSE:AGN), Eagle Pharmaceuticals Inc (NASDAQ:EGRX) - share market updates (press release)
06/10/16 04:42 PMSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX - [PR Newswire] - If you are a shareholder who purchased Eagle Pharmaceuticals securities during the Class Period, you have until August 1, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext.
06/10/16 03:53 PMEagle Pharmaceuticals (EGRX) Marked As A Barbarian At The Gate - TheStreet.com
06/10/16 03:20 PMWhy Eagle Pharmaceuticals, Inc. Skyrocketed 27.8% Today -
06/10/16 11:36 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 -- EGRX - [Marketwired] - The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Eagle Pharmaceuticals, Inc. between February 23, 2016...
06/10/16 07:31 AMEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : June 10, 2016 -
06/08/16 02:39 PMIMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Eagle Pharmaceuticals Inc. and Advises Investors With Losses to Contact the Firm - [Business Wire] - Goldberg Law PC announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. .
06/07/16 03:53 PMStocks inside Traders Spotlight: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) , Eagle Pharmaceuticals, Inc ... - Street Updates
06/07/16 03:53 PMEAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Alerts Eagle Pharmaceuticals, Inc. (NASDAQ ... - GlobeNewswire (press release)
06/07/16 07:30 AMEAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Alerts Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors to Securities Class Action and August 1, 2016 Lead Plaintiff Deadline - [GlobeNewswire] - SAN FRANCISCO, June 07, 2016-- The following statement is being issued by Hagens Berman Sobol Shapiro LLP:. To: All persons or entities who purchased or otherwise acquired securities of Eagle Pharmaceuticals ...
06/06/16 09:10 PMRyan & Maniskas, LLP Announces Class Action Lawsuit Against Eagle Pharmaceuticals Inc. - PR Newswire (press release)
06/06/16 08:34 PMINVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Eagle Pharmaceuticals Inc. and Advises Investors to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. .
06/06/16 06:15 PMRyan & Maniskas, LLP Announces Class Action Lawsuit Against Eagle Pharmaceuticals Inc. - [PR Newswire] - WAYNE, Pa., June 6, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the District of New Jersey on behalf of purchasers of Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals" or the "Company") (EGRX) common stock during the period between February 23, 2016 and March 18, 2016, inclusive (the "Class Period"). The complaint alleges that, on May 20, 2015, Eagle Pharmaceuticals submitted its New Drug Application ("NDA") for its blood-thinning drug, Kangio, to the U.S. Food and Drug Administration ("FDA").
About Eagle Pharmaceuticals

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care, orphan diseases and oncology areas. Its commercial products include Argatroban Injection, Ryanodex (dantrolene sodium) for injectable suspension, Diclofenac sodium misoprostol and Docetaxel Injection. Argatroban Injection treats thrombosis. Ryanodex treats malignant hyperthermia. Diclofenac sodium and misoprostol delayed-release tablets treat the signs and symptoms of osteoarthritis or rheumatoid arthritis. Docetaxel Injection treats breast cancer, non-small cell lung cancer, hormone refractory prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of the head and neck cancer. Its pipeline products include EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute concentrate solution), EP-3102 (bendamustine rapid infusion), EP-6101 (bivalirudin) and EP-5101 (pemetrexed).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EGRX
  • CUSIP:
Key Metrics:
  • Previous Close: $36.37
  • 50 Day Moving Average: $44.15
  • 200 Day Moving Average: $57.81
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $568.68M
  • Current Quarter EPS Consensus Estimate: $4.57 EPS
Additional Links:
Eagle Pharmaceuticals (NASDAQ:EGRX) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha